Ketim Technologies Advances Funding, Partnerships, and Mission in Transforming Maternal Mental Health

Brisbane, Australia – April 24, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has made significant strides in its mission to transform maternal mental health care, securing two grants totalling $2.25 million and delivering six investor pitches across Queensland, with two more scheduled interstate as part of its current $1 million raise.

Since February, the company has also completed its data room for full due diligence, participated in the AusBiotech IGP Innovation Cohort, and engaged in specialised classes, events, and workshops to accelerate its commercialisation pathway. These achievements mark a pivotal phase in Ketim Technologies’ growth as it advances toward clinical validation of its biomarker panel for the early detection of postpartum depression.

Behind these milestones lies the reality of the startup journey — long hours, relentless commitment, and the pressures of building a company from the ground up. Founder and CEO, Dr. Clarissa Yates, has spoken openly about the personal challenges faced during this period, including experiencing panic attacks for the first time in her life.

“Being a founder is not for the faint-hearted,” said Dr. Yates. “The pace is intense, the stakes are high, and the responsibility is constant. But I’m driven by a mission — to give mothers and families the tools to detect and manage mental illness earlier and more effectively. This is not just my job; it’s my calling.”

With a strong support network, a clear vision, and growing investor interest, Ketim Technologies is well-positioned to continue its trajectory toward delivering the world’s first clinical blood test for postpartum depression, alongside AI-driven predictive tools for mental health care.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au